Combined modality management of operable breast cancer.

Combined modality management of operable breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Combined modality management of operable breast cancer. Abstract Text:

A Rossi,P Valagussa,G Bonadonna,

Combined modality management of operable breast cancer. Publishing Authors By Initials

A Rossi,P Valagussa,G Bonadonna,

For similar diagnosis: prognosis research abstracts see: diagnosis: prognosis research

PUBMED ID PMID:

MEDLINE DATE:

Combined modality management of operable breast cancer. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 68

Page Numbers: 80-97

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 1978

Combined modality management of operable breast cancer. Information

Number of References: 66

LANGUAGE: eng

NlmUniqueID: 44671

Combined modality management of operable breast cancer. Keywords Mesh Terms:

KEYWORDS: Prognosis

MESH TERMS: chemically induced

Chemical & Substance for Abstract: Combined modality management of operable breast cancer. Information

Substance Name: Antineoplastic Agents

Registry Number: 0

Grant and Affiliation Information for Combined modality management of operable breast cancer.

AFFILIATION:

Country: GERMANY, WEST

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Combined modality management of operable breast cancer Related Publications

• Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
• Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
• Adriamycin in the adjuvant treatment of operable osteosarcoma.
• Alterations of glucose metabolism in type 2 diabetes mellitus. An overview.
• Assessment of microbiological and parasitological quality of composted wastes: health implications and hygienic measures.
• Clinical trials on adjuvant therapies in cancer: short-term and long-term results.
• Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma.
• Combined modality management of operable breast cancer.
• Current results with a combined treatment approach to localized Ewing's sarcoma.
• Future developments in adjuvant systemic therapy for high-risk breast cancer.
• Insulin sensitivity is correlated with subcutaneous but not visceral body fat in overweight and obese prepubertal children.
• Laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease.
• Long-term sequelae from adjuvant chemotherapy.
• Methotrexate (NSC-740) and bleomycin (NSC-125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix.
• Methyl-CCNU (NSCU-95441) versus methyl-CCNU plus cyclophosphamide (NSC-26271) in advanced gastrointestinal cancer.
• Primary chemotherapy in surgically resectable breast cancer: the experience of the Milan Cancer Institute.
• Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies.
• Response and survival in advanced breast cancer after two non-cross-resistant combinations.
• Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
• Salvage treatments in relapsing resectable breast cancer.
• Second malignancies in Hodgkin's disease: a complication of certain forms of treatment.
• VIII. Women's health perception and breast cancer: issues of fertility, hormone substitution, and cancer prevention.
• What did we learn from the results of the international overview about the effects of endocrine therapy?